Found 456 with Last Name = 'lesch' and Initial = 'b' 
Affinity DataKi: 0.0900nMAssay Description:Inhibition of recombinant human Cathepsin S expressed in baculovirus infected insect cells using Z-VVR-AMC as substrate preincubated for 15 mins foll...More data for this Ligand-Target Pair
Affinity DataKi: 0.0900nMAssay Description:Inhibition of recombinant human Cathepsin S expressed in baculovirus infected insect cells using Z-VVR-AMC as substrate preincubated for 15 mins foll...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 0.100nMAssay Description:The agonistic or antagonistic effect of the substances to be tested on the rat-species vanilloid receptor 1 (VR1/TRPV1) can be determined using the f...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.100nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.100nM ΔG°: -59.4kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 0.100nMAssay Description:The agonistic or antagonistic effect of the substances to be tested on the rat-species vanilloid receptor 1 (VR1/TRPV1) can be determined using the f...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.100nM ΔG°: -59.4kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 0.200nMAssay Description:The agonistic or antagonistic effect of the substances to be tested on the rat-species vanilloid receptor 1 (VR1/TRPV1) can be determined using the f...More data for this Ligand-Target Pair
Affinity DataKi: 0.200nMAssay Description:Inhibition of recombinant human Cathepsin S expressed in baculovirus infected insect cells using Z-VVR-AMC as substrate preincubated for 15 mins foll...More data for this Ligand-Target Pair
Affinity DataKi: 0.200nMAssay Description:Inhibition of recombinant human Cathepsin S expressed in baculovirus infected insect cells using Z-VVR-AMC as substrate preincubated for 15 mins foll...More data for this Ligand-Target Pair
Affinity DataKi: 0.25nMAssay Description:Inhibition of recombinant human Cathepsin S expressed in baculovirus infected insect cells using Z-VVR-AMC as substrate preincubated for 15 mins foll...More data for this Ligand-Target Pair
Affinity DataKi: 0.25nMAssay Description:Inhibition of recombinant human Cathepsin S expressed in baculovirus infected insect cells using Z-VVR-AMC as substrate preincubated for 15 mins foll...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nM ΔG°: -56.5kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nM ΔG°: -56.5kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nM ΔG°: -56.5kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nM ΔG°: -56.5kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO-K1 cells assessed as inhibition of capsaicin-induced Ca2+ response treated with compound 6 mins p...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO-K1 cells assessed as inhibition of capsaicin-induced Ca2+ response treated with compound 6 mins p...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO cells assessed as inhibition of capsaicin-induced TRPV1 activation by FLIPR methodMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO cells assessed as inhibition of capsaicin-induced TRPV1 activation by FLIPR methodMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO cells assessed as inhibition of capsaicin-induced TRPV1 activation by FLIPR methodMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 0.350nMAssay Description:The agonistic or antagonistic effect of the substances to be tested on the rat-species vanilloid receptor 1 (VR1/TRPV1) can be determined using the f...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 0.400nMAssay Description:The agonistic or antagonistic effect of the substances to be tested on the rat-species vanilloid receptor 1 (VR1/TRPV1) can be determined using the f...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.400nM ΔG°: -55.8kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.400nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO-K1 cells assessed as inhibition of capsaicin-induced Ca2+ response treated with compound 6 mins p...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 0.400nMAssay Description:The agonistic or antagonistic effect of the substances to be tested on the rat-species vanilloid receptor 1 (VR1/TRPV1) can be determined using the f...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.400nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.5nM ΔG°: -55.2kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.5nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO-K1 cells assessed as inhibition of capsaicin-induced Ca2+ response treated with compound 6 mins p...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.5nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO-K1 cells assessed as inhibition of capsaicin-induced Ca2+ response treated with compound 6 mins p...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.600nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO-K1 cells assessed as inhibition of capsaicin-induced Ca2+ response treated with compound 6 mins p...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.600nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO-K1 cells assessed as inhibition of capsaicin-induced Ca2+ response treated with compound 6 mins p...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.600nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO-K1 cells assessed as inhibition of capsaicin-induced Ca2+ response treated with compound 6 mins p...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.600nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.600nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO-K1 cells assessed as inhibition of capsaicin-induced Ca2+ response treated with compound 6 mins p...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.700nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Affinity DataKi: 0.700nMAssay Description:Recombinant human cathepsins (CatS, CatK, CatL, CatB) were purchased from a Enzo Life Sciences. All assays were carried out in 96-well format using a...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.700nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.700nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Affinity DataKi: 0.800nMAssay Description:Recombinant human cathepsins (CatS, CatK, CatL, CatB) were purchased from a Enzo Life Sciences. All assays were carried out in 96-well format using a...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.800nM ΔG°: -54.0kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.900nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO-K1 cells assessed as inhibition of capsaicin-induced Ca2+ response treated with compound 6 mins p...More data for this Ligand-Target Pair
Affinity DataKi: 1nMAssay Description:Recombinant human cathepsins (CatS, CatK, CatL) were purchased from a Enzo Life Sciences. All assays were carried out in 96-well format using a buffe...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 1nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 1nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 1nMAssay Description:Antagonist activity at human TRPV1 expressed in CHO-K1 cells assessed as inhibition of capsaicin-induced Ca2+ response treated with compound 6 mins p...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 1.10nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 1.20nMAssay Description:The agonistic or antagonistic effect of the substances to be tested on the rat-species vanilloid receptor 1 (VR1/TRPV1) can be determined using the f...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 1.20nM ΔG°: -53.0kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
